CY1109754T1 - Μεθοδος ανακτησης βιολογικα ενεργου ανθρωπινου g-csf απο σωματα εγκλεισμου - Google Patents

Μεθοδος ανακτησης βιολογικα ενεργου ανθρωπινου g-csf απο σωματα εγκλεισμου

Info

Publication number
CY1109754T1
CY1109754T1 CY20101100082T CY101100082T CY1109754T1 CY 1109754 T1 CY1109754 T1 CY 1109754T1 CY 20101100082 T CY20101100082 T CY 20101100082T CY 101100082 T CY101100082 T CY 101100082T CY 1109754 T1 CY1109754 T1 CY 1109754T1
Authority
CY
Cyprus
Prior art keywords
csf
active human
biological active
including bodies
reduced glutathione
Prior art date
Application number
CY20101100082T
Other languages
English (en)
Inventor
Ulrich Kurt Blaschke
Arndt Dietrich
Bernhard Janowski
Jörg Schäffner
Original Assignee
Bioceuticals Arzneimittel Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35406424&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1109754(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bioceuticals Arzneimittel Ag filed Critical Bioceuticals Arzneimittel Ag
Publication of CY1109754T1 publication Critical patent/CY1109754T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Steroid Compounds (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε μέθοδο ανάκτησης βιολογικά ενεργού ανθρώπινου G-CSF από σώματα εγκλεισμού (inclusion bodies), η οποία χαρακτηρίζεται από το ότι, κατά τη διαλυτοποίηση του G-CSF, ως αναγωγικό μέσο χρησιμοποιείται ανηγμένη γλουταθειόνη και, για την αναδίπλωση του G-CSF, ως οξειδοαναγωγικό σύστημα χρησιμοποιείται μείγμα ανηγμένης και οξειδωμένης γλουταθειόνης.
CY20101100082T 2004-08-27 2010-01-27 Μεθοδος ανακτησης βιολογικα ενεργου ανθρωπινου g-csf απο σωματα εγκλεισμου CY1109754T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004041639A DE102004041639A1 (de) 2004-08-27 2004-08-27 Verfahren zur Gewinnung von biologisch aktivem humanen G-CSF aus Inclusion Bodies
EP05107881A EP1630173B1 (de) 2004-08-27 2005-08-29 Verfahren zur Gewinnung von biologisch aktivem humanen G-CSF aus Inclusion Bodies

Publications (1)

Publication Number Publication Date
CY1109754T1 true CY1109754T1 (el) 2014-09-10

Family

ID=35406424

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100082T CY1109754T1 (el) 2004-08-27 2010-01-27 Μεθοδος ανακτησης βιολογικα ενεργου ανθρωπινου g-csf απο σωματα εγκλεισμου

Country Status (10)

Country Link
EP (1) EP1630173B1 (el)
AT (1) ATE447584T1 (el)
CY (1) CY1109754T1 (el)
DE (2) DE102004041639A1 (el)
DK (1) DK1630173T3 (el)
ES (1) ES2336007T3 (el)
HR (1) HRP20100053T1 (el)
PL (1) PL1630173T3 (el)
PT (1) PT1630173E (el)
SI (1) SI1630173T1 (el)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005033250A1 (de) * 2005-07-15 2007-01-18 Bioceuticals Arzneimittel Ag Verfahren zur Reinigung von G-CSF
GB0605684D0 (en) * 2006-03-21 2006-05-03 Sicor Biotech Uab Method For Purifying Granulocyte-Colony Stimulating Factor
WO2008096370A2 (en) * 2007-02-05 2008-08-14 Natco Pharma Limited An efficient and novel purification method of recombinant hg-csf
EP2445924B2 (en) 2009-06-25 2023-12-13 Amgen Inc. Capture purification processes for proteins expressed in a non-mammalian system
WO2011113601A1 (en) * 2010-03-17 2011-09-22 Biogenerix Ag Method for obtaining biologically active recombinant human g-csf
CN101830977B (zh) * 2010-05-07 2012-01-25 厦门特宝生物工程股份有限公司 一种重组人粒细胞刺激因子的纯化方法
HUP1200172A2 (en) 2012-03-19 2013-10-28 Richter Gedeon Nyrt Methods for refolding g-csf from inclusion bodies
HUP1200171A1 (hu) 2012-03-19 2013-09-30 Richter Gedeon Nyrt Módszerek polipeptidek elõállítására
US9982012B2 (en) 2013-03-29 2018-05-29 Dr. Reddy's Laboratories Limited Refolding of granulocyte colony stimulating factor
WO2019175633A1 (en) * 2018-03-15 2019-09-19 Petiva Private Limited Methods for refolding sucrose isomerase

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL86090A (en) * 1987-04-16 1993-03-15 Cetus Oncology Corp Production of purified, biologically active, bacterially produced recombinant human csf-1
DE4014750A1 (de) 1990-05-08 1991-11-14 Boehringer Mannheim Gmbh Muteine des granulozyten-stimulierenden faktors (g-csf)
WO1993003134A1 (en) * 1991-07-29 1993-02-18 Immunex Corporation Process for isolating and purifying recombinant interleukin-7
IL152804A0 (en) * 2000-05-16 2003-06-24 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
GB0019375D0 (en) * 2000-08-07 2000-09-27 Int Centre Genetic Eng & Bio Method of polypeptide renaturation
US20040116663A1 (en) * 2001-01-16 2004-06-17 Soren Buus Method for refolding of proteins
JPWO2005033307A1 (ja) * 2003-09-30 2006-12-14 技術研究組合 生物分子工学研究所 新規のリフォールディング方法およびその方法によって得られたタンパク質

Also Published As

Publication number Publication date
EP1630173B1 (de) 2009-11-04
EP1630173A2 (de) 2006-03-01
HRP20100053T1 (hr) 2010-03-31
SI1630173T1 (sl) 2010-03-31
DK1630173T3 (da) 2010-03-15
PT1630173E (pt) 2010-02-12
EP1630173A3 (de) 2006-03-08
DE102004041639A1 (de) 2006-03-02
DE502005008432D1 (de) 2009-12-17
ATE447584T1 (de) 2009-11-15
PL1630173T3 (pl) 2010-04-30
ES2336007T3 (es) 2010-04-07

Similar Documents

Publication Publication Date Title
CY1109754T1 (el) Μεθοδος ανακτησης βιολογικα ενεργου ανθρωπινου g-csf απο σωματα εγκλεισμου
MX2019014023A (es) Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer.
CY1112323T1 (el) Παραγωγη και καθαρισμος της il-29
DE602005026931D1 (de) Verwendung von vorstufen von enkephalinen und/oder deren fragmenten in der medizinischen diagnostik
WO2007110231A3 (en) MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES
BRPI0618488A2 (pt) proteìnas de fusão de ìntron de fator de crescimento de hepatócito
PE20050477A1 (es) Terapia de combinacion para la infeccion de hcv
ATE411038T1 (de) S100 protein als aktivator neutrophiler zellen zur verminderung der neutropenie bei der krebsbehandlung
ATE509958T1 (de) Gegen cathepsin s gerichtete therapie
BRPI0416434A (pt) métodos para aumentar a atividade de uma proteìna de ácido esfingomielinase (asm), para estender a meia-vida e prolongar a atividade de uma proteìna asm purificada, para aumentar a produção de uma proteìna asm recombinante através de uma célula hospedeira, e usos de uma composição de asm tipo alelo-selvagem, purificada e um composto análogo de ceramida ou esfingomielina, e de um composto análogo de ceramida ou de esfingomielina
Suku et al. Anti-ageing protein β-klotho rejuvenates diabetic stem cells for improved gene-activated scaffold based wound healing
WO2010123699A3 (en) Compositions, kits and methods for promoting ischemic and diabetic wound healing
DE60236109D1 (de) Klasse-ii-cytokinrezeptoren und deren verwendungen
Pitocco et al. Severe leucopenia associated with sitagliptin use
BRPI0407266A (pt) Composição de droga citostática
Jabbar et al. Emerging evidence of the significance of thioredoxin-1 in hematopoietic stem cell aging
Weisdorf et al. Blood and marrow transplant clinical trials network (BMT CTN): addressing unanswered questions
FR2894594B1 (fr) Test predictif de reponse therapeutique du cancer du sein
ATE475099T1 (de) Beurteilung der biologischen aktivität von hgf (hepatocyte growth factor)
Kurmangulov et al. Substantive navigation systems in medical institutions: a lean perspective
AR053284A1 (es) Terapia genica de interferon -beta usando un sistema mejorado de expresion regulada
WO2004016813A3 (en) Hnf1 alpha as a tumor suppressor gene, and diagnostic and therapeutic applications thereof
Clement et al. Standard Measures during Spaceflight
ATE416194T1 (de) Verwendung von cardiotrophin bei leberkrankheiten
Duarte et al. Vinorelbine-Based Hematopoietic Stem-Cell Mobilization: A More Effective, Low-Cost Alternative to Conventional Chemotherapy